According to the updated NCCN guideline, patients with HER2 amplified and RAS/RAF wild type CRC are eligible candidates for fam-trastuzumab deruxtecan-nxki or a combination of trastuzumab with pertuzumab or lapatinib or tucatinib35. The gene discussed is ERBB2; the disease is colorectal carcinoma.